Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Volkswagen Q1 2026 Sales Decline Amid China and U.S. Market Pressures 
 & Lead Plaintiff Deadline: March 28, 2017 - EconoTimes)
NEW YORK, Feb. 20, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Egalet Corporation (“Egalet” or the “Company”) (NASDAQ:EGLT) and certain of its officers, and is on behalf of shareholders who purchased or otherwise acquired Egalet securities between December 15, 2015, and January 9, 2017, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/eglt.
The class action lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose material adverse information about its lead product, ARYMO ER and the likelihood that it would receive oral abuse-deterrent labeling.
On January 9, 2017, Egalet released a statement announcing the approval of its product Arymo ER. Later that day, the U.S. Federal Drug Administration stated that a competitor product MorphaBond “has marketing exclusivity for labeling describing the expected reduction of abuse of single-entity extended-release morphine by the intranasal route due to physicochemical properties.” Following this news, Egalet stock dropped, thus damaging investors.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/eglt or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Egalet you have until March 28, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
